|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioTransplant Inc., of Charlestown, Mass., received CE mark approval for its third HDM cell separation product, the Eligix CD8-SC Cell Separation System, for ex vivo use in patients receiving allogeneic bone marrow and peripheral stem cell transplantation. BioTransplant's distribution partner, Gambro BCT, a wholly owned subsidiary of Gambro AB, of Stockholm, Sweden, markets in Europe the Eligix family including the CD8-DLI and BCell-SC systems for use in bone marrow, stem cell and donor leukocyte transplants.
Boston Life Sciences Inc., of Boston, issued a $4 million 10 percent convertible senior secured promissory note to a single institutional investor. The note ...